We have shown previously that Listeria monocytogenes, a gram-positive, facultative intracellular bacterium, is a potent vector for targeting tumor-specific antigens to the immune system. After parenteral administration, we observed protection against both renal and colorectal mouse tumors and regression of established renal tumors. In the present study, we have exploited the fact that the normal route of infection of this organism is through the gut We show that an L. monocytogenes recombinant that expresses a model tumor antigen is an effective cancer immu-notherapeutic agent when delivered orally in that it causes regression of established, macroscopic mouse renal and colorectal tumors expressing the same antigen.
|Original language||English (US)|
|Number of pages||4|
|State||Published - May 15 1995|
ASJC Scopus subject areas
- Cancer Research